April 24th 2024
Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Recap: Noninferiority Comparison of Acalabrutinib and Ibrutinib for Previously Treated CLL
August 28th 2022Michael R. Bishop, MD, and Bruce B. Bank, MD, review results from the ELEVATE-RR noninferiority trial on acalabrutinib versus ibrutinib in CLL, and discuss the clinical implications of the findings.
EMA Accepts Marketing Authorization Application for Decitabine and Cedazuridine in Adult AML
August 24th 2022Adult patients with acute myeloid leukemia who are not eligible for treatment with standard induction chemotherapy may benefit from treatment with decitabine and cedazuridine, the marketing authorization application for which was accepted by the European Medicines Agency.
FDA Grants Fast Track and Rare Pediatric Disease Designation to WU-CART-007 in R/R T-Cell ALL/LBL
July 20th 2022WU-CART-007 was granted fast track and rare pediatric disease designation by the FDA for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.
Venetoclax Plus Obinutuzumab Yield PFS Improvement in Untreated CLL, With or Without Ibrutinib
June 16th 2022Patients with treatment-naïve chronic lymphocytic leukemia who were treated with venetoclax and obinutuzumab with or without ibrutinib experienced a progression-free survival benefit compared with standard chemoimmunotherapy.
Ph– B-Cell ALL Achieves MRD Negativity With Inotuzumab Plus Hyper-CVAD and Blinatumomab
June 4th 2022Chances of reaching complete remission and minimal residual disease negativity were greater with the addition of inotuzumab to hyper-CVAD with sequential blinatumomab in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic lymphoma.
Cross Q&A: The Memorial Sloan-Kettering Mavericks
The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Outcome Determination for Adolescents and Young Adults with ALL
Xiaoli Mi, MD, presents data from a paper in Blood on the determination of outcomes for adolescents and young adults with ALL.
Pediatric-Inspired Chemotherapy Incorporating Pegaspargase in Adults with Ph-ALL
Varun Narendra, MD, describes a clinical trial that studied whether pediatric-inspired ALL regimens could be used in older adults with Philadelphia chromosome–positive ALL.